生命科学资讯
生物技术与制药领域的最新动态
QuantX raises $85M Series B from Lilly, Sanofi Ventures
Lilly buys ‘in vivo’ CAR-T maker Orna, extending streak of genetic medicine deals
Despite FDA’s crackdown, pharma is still spending millions on ads
武田制药与Iambic Therapeutics签署17亿美元AI药物发现协议。
Takeda inks $1.7B AI drug discovery deal with Iambic Therapeutics
礼来以24亿美元收购Orna，进军体内CAR-T领域。
Lilly buys Orna in $2.4B deal to enter in vivo CAR-T arena
Lilly bets again on China drugs; Roche showcases MS data
赛默飞世尔科技公司申请发行四部分高级票据，规模未披露 - 市场观察网
Thermo Fisher Scientific Inc files for four-part senior notes offering size not disclosed - marketscreener.com
礼来以24亿美元收购Orna，加入体内CAR-T竞赛。
Lilly joins in vivo CAR-T sprint with $2.4B Orna acquisition
Galux完成2900万美元B轮融资；CSL与Memo达成合作
Galux raises $29M Series B; CSL teams up with Memo
通往Illumina之路 - Illumina
My path to Illumina - Illumina
Innovent-Lilly $8.5B deal signals new China inflection point
2026年2月2日至6日最大赢家和输家
Biggest gainers and losers for Feb. 2-6, 2026
BD完成生物科学与诊断解决方案业务与沃特世公司的合并 - 贝克顿迪金森
BD Completes Combination of Biosciences & Diagnostic Solutions Business with Waters Corporation - Becton Dickinson
#ACTRIMS26：罗氏多发性硬化症药物芬布替尼优于奥瑞珠单抗，降低残疾进展风险12%
#ACTRIMS26: Roche’s MS drug fenebrutinib beats Ocrevus, cutting risk of disability progression by 12%
CUL5 E3 ubiquitin ligase regulates the evasion of bladder cancer cells to CD8+ T cell-mediated killing by inhibiting autophagy
武田制药与Iambic签署多年AI药物研发合作协议。
Takeda, Iambic sign multiyear R&D deal for AI drug discovery
新诊断方法为阿尔茨海默病、帕金森病及其他疾病定义药物靶点
New diagnostics define drug targets for Alzheimer’s, Parkinson’s and beyond
Venenum Biodesign公布新型MOGAT2抑制剂
Venenum Biodesign discloses new MOGAT2 inhibitors
韩国研究人员报告新型HER1/HER2突变抑制剂
Korean researchers report new HER1/HER2 mutant inhibitors